PO.MCB10.02 · 分子与细胞生物学

长链非编码RNA RAMS11促进结直肠癌的DNA损伤应答

Long noncoding RNA, RAMS11, promotes DNA damage response in colorectal cancer

海报缩略图:长链非编码RNA RAMS11促进结直肠癌的DNA损伤应答
编号 5904 展板 11 时间 4/21 02:00–05:00 区域 Section 20 主讲 Yesol Kim, MS;PhD
分会场 Functional Roles of Noncoding RNAs in Cancer Progression, Metabolism, and Therapy Response
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Yesol Kim, Shilpa Hebbar, Nicole White, Amy Ly, Christopher A. Maher

Washington University School of Medicine in St. Louis, Saint Louis, MO

摘要 Abstract

中文摘要
结直肠癌仍是全球癌症相关死亡的主要原因之一,约30%的患者对标准化疗产生耐药性。表现出DNA损伤应答(DDR)和DNA修复通路缺陷的肿瘤表现出增加的基因组不稳定性,这可能表现为耐药性,突显了治疗性靶向DDR的临床意义。虽然结直肠癌中编码蛋白的驱动因素已被广泛表征,但持续的治疗挑战强调了阐明驱动癌症发展的新机制的必要性。在此,我们发现,通过对癌症基因组图谱(TCGA)数据集的分析显示,长链非编码RNA(lncRNA)RAMS11在转移性结直肠癌中显著上调,尤其是在携带p53突变的肿瘤中。p53突变型转移性结直肠癌是一类通常依赖ATR/Chk1检查点存活的群体。然而,通过小分子药物筛选,我们发现高RAMS11细胞对ATR和CHK1抑制剂表现出耐药性。虽然RAMS11驱动高复制应激状态(如RAMS11过表达细胞中RAD51焦点增加所证实),但它同时赋予对ATR和CHK1抑制剂的深度耐药性。在机制上,我们通过证明RAMS11减弱检查点应答来解决这一悖论,即使在复制应激下也导致pChk1激活减弱。我们发现这些细胞现在关键性地依赖于一条替代修复通路——同源重组(HR)——来解决DNA损伤。事实上,我们的功能研究证实,敲低RAMS11显著损害HR修复能力。这项工作确定了RAMS11在细胞中重新导向DDR依赖性,揭示了一种内在化疗耐药性的新机制,并提示了靶向HR通路的合成致死策略。总之,这些发现提示,RAMS11的异常过表达破坏了DDR并促进DNA复制应激,从而导致化疗耐药性。阐明RAMS11的机制将为结直肠癌的化疗耐药性提供关键见解。
查看英文原文 English abstract
Colorectal cancer remains a leading cause of cancer-related mortality worldwide, with approximately 30% of patients developing resistance to standard chemotherapy. Tumors that exhibit defects in DNA damage response (DDR) and DNA repair pathways exhibit increased genomic instability, which can manifest as resistance, underscoring the clinical significance of therapeutic targeting of DDR. While protein-coding drivers in colorectal cancer have been extensively characterized, persistent therapeutic challenges emphasize the necessity of elucidating novel mechanisms driving cancer development. Here, we found that the long noncoding RNA (lncRNA) RAMS11 is significantly upregulated in metastatic colorectal cancer, particularly in tumors harboring p53 mutations, as revealed by analyses of The Cancer Genome Atlas (TCGA) datasets. p53-mutant metastatic CRC, a population normally reliant on the ATR/Chk1 checkpoint for survival. However, from small-molecule drug screening, we discovered that high RAMS11 cells showed resistance to ATR and CHK1 inhibitors. While RAMS11 drives a state of high replication stress, as evidenced by increased RAD51 foci in RAMS11-overexpressing cells, it simultaneously confers profound resistance to ATR and CHK1 inhibitors. Mechanistically, we resolve this paradox by demonstrating that RAMS11 attenuates the checkpoint response, leading to a blunted pChk1 activation even under replication stress. We find these cells are now critically dependent on an alternative repair pathway, Homologous Recombination (HR), to resolve the DNA damage. Indeed, our functional studies confirm that knockdown of RAMS11 significantly impairs HR repair capacity. This work identifies that RAMS11 reroutes DDR dependencies in cells, revealing a new mechanism of intrinsic chemoresistance and suggesting a synthetic lethal strategy targeting the HR pathway. Collectively, these findings suggest that aberrant overexpression of RAMS11 disrupts the DDR and promotes DNA replication stress, thereby leading to chemoresistance. Elucidating the mechanism of RAMS11 will provide critical insights into chemoresistance in colorectal cancer.
利益披露 Disclosure
Y. Kim, None.. S. Hebbar, None.. N. White, None.. A. Ly, None.. C. A. Maher, None.

← 返回 AACR 2026 检索